TRACE: Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis

External trial evidence can inform oncology trial design, but broad pooling may produce benchmarks poorly aligned with the planned population. We developed TRACE (Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis), combining eligibility screening, Bayesian compatibility assessment using published baseline characteristics, and hierarchical survival modeling. An integrated compatibility score based on the largest standardized difference in jointly reported characteristics identifies compatible external trials. Their reconstructed control-arm survival data are synthesized using a hierarchical beta-Stacy process to generate a predictive survival benchmark. We evaluated TRACE using eleven randomized phase III trials in first-line HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma. With KEYNOTE-859 as the target, three external trials were selected. TRACE predicted a control-arm median overall survival of 11.8 months (95% posterior predictive interval, 8.9-15.2), compared with an observed median of 11.8 months (95% confidence interval, 10.9-12.7). In leave-one-trial-out validation, seven targets had compatible external evidence. Predictive intervals contained the observed median for all seven. In comparison, confidence intervals from Kaplan-Meier estimates pooling all other trials' control arms contained it for five. Mean pointwise curve coverage was 92% for TRACE and 59% for pooled Kaplan-Meier. For four targets without compatible external evidence, TRACE returned a weakly informative prior predictive benchmark. TRACE provides a transparent approach to selecting relevant external evidence and generating benchmarks for oncology trial planning.

Authors

Publication Details

Journal
arXiv (Cornell University)
Published
2026-11-12
DOI
https://doi.org/10.48550/arxiv.2611.16870
Primary Topic
Statistical Methods in Clinical Trials
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

TRACE: Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis

Satrajit Roychoudhury, Guannan Gong, Tulika Rudra Gupta, Liangze Ke et al.
arXiv (Cornell University)
Statistical Methods in Clinical Trials
preprint

TRACE: Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis

Satrajit Roychoudhury, Guannan Gong, Tulika Rudra Gupta, Liangze Ke, Pavan Challa, Raghav Sundar, Tianzhi Tang, Wei Wei
preprint en

Abstract

External trial evidence can inform oncology trial design, but broad pooling may produce benchmarks poorly aligned with the planned population. We developed TRACE (Target-Trial Relevance Assessment and Compatibility-Guided Evidence Synthesis), combining eligibility screening, Bayesian compatibility assessment using published baseline characteristics, and hierarchical survival modeling. An integrated compatibility score based on the largest standardized difference in jointly reported characteristics identifies compatible external trials. Their reconstructed control-arm survival data are synthesized using a hierarchical beta-Stacy process to generate a predictive survival benchmark. We evaluated TRACE using eleven randomized phase III trials in first-line HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma. With KEYNOTE-859 as the target, three external trials were selected. TRACE predicted a control-arm median overall survival of 11.8 months (95% posterior predictive interval, 8.9-15.2), compared with an observed median of 11.8 months (95% confidence interval, 10.9-12.7). In leave-one-trial-out validation, seven targets had compatible external evidence. Predictive intervals contained the observed median for all seven. In comparison, confidence intervals from Kaplan-Meier estimates pooling all other trials' control arms contained it for five. Mean pointwise curve coverage was 92% for TRACE and 59% for pooled Kaplan-Meier. For four targets without compatible external evidence, TRACE returned a weakly informative prior predictive benchmark. TRACE provides a transparent approach to selecting relevant external evidence and generating benchmarks for oncology trial planning.

arXiv (Cornell University)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon